Brady Williams speaks during hearings over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. John Boal Photography
Add to Cart Add to Lightbox Download
